Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norspan for postherpetic neuralgia
ACTRN12608000242325Phase 4Active, not recruiting
- Sponsor
- Mundipharma
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of buprenorphine in postherpetic neuralgia (PHN) (2 arms), sponsored by Mundipharma. Primary endpoint: Rate of response for pain relief. Started May 2008; status: active, not recruiting.
02
Drugs
buprenorphine
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ACTRN12608000242325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000242325.